The UCLA experience with type I interferons in hairy cell leukemia.
Fifty-one patients have been entered on clinical trials of interferon in hairy cell leukemia. Hematological improvement was seen in 23 (96%) patients treated with recombinant alpha-2b-interferon, nine patients (69%) treated with lymphoblastoid alpha-N1-interferon, and, thus far, in five (71%) patients beginning therapy with recombinant beta-serine-interferon. All patients showing improvement have done so within 1 year and most within 6 months. Rapidity of response, duration of follow-up, and toxicity data are presented.
Glaspy
J A
JA
Department of Medicine, UCLA School of Medicine 90024.
Jacobs
A D
AD
Golde
D W
DW
D002140:California; D002986:Clinical Trials as Topic; D006410:Hematopoiesis; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta; D007943:Leukemia, Hairy Cell / Q000628:therapy*; D007958:Leukocyte Count; D010976:Platelet Count; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013997:Time Factors
D007370:Interferon Type I; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a